KYMFABI

Serial Number 79254291
Registration 5830778
700

Registration Progress

Application Filed
Feb 1, 2019
Under Examination
Approved for Publication
May 8, 2019
Published for Opposition
May 28, 2019
Registered
Aug 13, 2019

Attorney Assistance

Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20190813) (Grace Period Filing)
Due: Feb 13, 2026 Grace Period - 59 days
Original deadline was Aug 13, 2025 (overdue)

Trademark Image

KYMFABI

Basic Information

Serial Number
79254291
Registration Number
5830778
Filing Date
February 1, 2019
Registration Date
August 13, 2019
Published for Opposition
May 28, 2019
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 13, 2019
Registration
Registered
Classes
005

Rights Holder

Idorsia Pharmaceuticals Ltd

99
Address
Hegenheimermattweg 91
CH-4123 Allschwil
CH

Ownership History

Idorsia Pharmaceuticals Ltd

Original Applicant
99
CH

Idorsia Pharmaceuticals Ltd

Owner at Publication
99
CH

Idorsia Pharmaceuticals Ltd

Original Registrant
99
CH

USPTO Deadlines

Next Deadline
In Grace Period
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20190813)
Due Date
August 13, 2025
Grace Period Ends
February 13, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

13 events
Date Code Type Description Documents
Dec 11, 2020 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Oct 11, 2019 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Sep 23, 2019 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Sep 23, 2019 FIMP P FINAL DISPOSITION PROCESSED Loading...
Sep 12, 2019 GPAR P GRANT OF PROTECTION CREATED, TO BE SENT TO IB Loading...
Aug 13, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 28, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 8, 2019 NPUB O NOTICE OF PUBLICATION Loading...
Apr 13, 2019 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 13, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 22, 2019 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Mar 18, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 14, 2019 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical products for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, excluding products used in cell therapy or gene therapy or for treatment of blood diseases
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005